Moomoo AI 已提取核心信息
Senti Biosciences, Inc., a Delaware-incorporated biotechnology company, has been granted an additional 180-day period to meet Nasdaq's minimum bid price requirement. The company's common stock, trading under the symbol SNTI, was initially notified of non-compliance with the $1.00 minimum bid price rule after closing below this threshold for 30 consecutive business days. The initial 180-day grace period ended on February 5, 2024, without achieving compliance. Consequently, Senti Biosciences applied for and was approved to transfer its listing from The Nasdaq Global Market to The Nasdaq Capital Market, effective January 25, 2024. This transfer allows the company to benefit from a second 180-day grace period, which extends until August 5, 2024, to regain compliance. During this period, the company must maintain a closing bid price...Show More
Senti Biosciences, Inc., a Delaware-incorporated biotechnology company, has been granted an additional 180-day period to meet Nasdaq's minimum bid price requirement. The company's common stock, trading under the symbol SNTI, was initially notified of non-compliance with the $1.00 minimum bid price rule after closing below this threshold for 30 consecutive business days. The initial 180-day grace period ended on February 5, 2024, without achieving compliance. Consequently, Senti Biosciences applied for and was approved to transfer its listing from The Nasdaq Global Market to The Nasdaq Capital Market, effective January 25, 2024. This transfer allows the company to benefit from a second 180-day grace period, which extends until August 5, 2024, to regain compliance. During this period, the company must maintain a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. Senti Biosciences has indicated that it may consider a reverse stock split as a potential remedy to address the bid price deficiency if necessary. The company cautions that there is no assurance of regaining compliance within the second grace period, and failure to do so may result in delisting. The company's CEO, Timothy Lu, M.D., Ph.D., signed the report dated February 6, 2024.
特拉华州注册成立的生物技术公司Senti Biosciences, Inc. 已获准再延长180天以满足纳斯达克的最低出价要求。该公司的普通股交易代码为SNTI，在连续30个工作日收盘低于该门槛后，最初被告知未遵守1.00美元的最低出价规则。最初的 180 天宽限期于 2024 年 2 月 5 日结束，但没有达到合规要求。因此，Senti Biosciences申请并获准将其上市从纳斯达克全球市场转移到纳斯达克资本市场，自2024年1月25日起生效。此次转让使公司能够享受第二个180天的宽限期，该宽限期延长至2024年8月5日，以恢复合规。在此期间，公司必须至少连续10个工作日将收盘价维持在至...展开全部
特拉华州注册成立的生物技术公司Senti Biosciences, Inc. 已获准再延长180天以满足纳斯达克的最低出价要求。该公司的普通股交易代码为SNTI，在连续30个工作日收盘低于该门槛后，最初被告知未遵守1.00美元的最低出价规则。最初的 180 天宽限期于 2024 年 2 月 5 日结束，但没有达到合规要求。因此，Senti Biosciences申请并获准将其上市从纳斯达克全球市场转移到纳斯达克资本市场，自2024年1月25日起生效。此次转让使公司能够享受第二个180天的宽限期，该宽限期延长至2024年8月5日，以恢复合规。在此期间，公司必须至少连续10个工作日将收盘价维持在至少1.00美元。Senti Biosciences表示，如有必要，它可能会考虑将反向股票拆分作为解决出价缺陷的潜在补救措施。该公司警告说，无法保证在第二个宽限期内恢复合规，不这样做可能会导致退市。该公司首席执行官、医学博士、博士蒂莫西·卢签署了2024年2月6日的报告。
有用
没用